Document:

Exhibit 10.12

 

INDEMNIFICATION AGREEMENT

 

This Indemnification Agreement (this “Agreement”) is made as of               , 20      by and between Merrimack Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and                                (the “Indemnitee”), a director and/or officer of the Corporation.

 

WHEREAS, it is essential to the Corporation to retain and attract as directors and officers the most capable persons available;

 

WHEREAS, the substantial increase in corporate litigation subjects directors and officers to expensive litigation risks at the same time that the availability of directors’ and officers’ liability insurance has been severely limited;

 

WHEREAS, it is now and has always been the express policy of the Corporation to indemnify its directors and officers;

 

WHEREAS, the Indemnitee does not regard the protection available under the Corporation’s Restated Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve or continue to serve as a director or officer without adequate protection; and

 

WHEREAS, the Corporation desires the Indemnitee to serve, or continue to serve, as a director or officer of the Corporation.

 

NOW THEREFORE, the Corporation and the Indemnitee do hereby agree as follows:

 

1.             Agreement to Serve.  The Indemnitee agrees to serve or continue to serve as a director and/or officer of the Corporation for so long as the Indemnitee is duly elected or appointed or until such time as the Indemnitee tenders a resignation in writing or becomes otherwise incapable of serving due to his or her disability or death.

 

2.             Definitions.  As used in this Agreement:

 

(a)           The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternative dispute resolution proceeding, administrative hearing or other proceeding, whether brought by or in the right of the Corporation or otherwise and whether of a civil, criminal, administrative or investigative nature, and any appeal therefrom.

 

(b)           The term “Corporate Status” shall mean the status of a person who is or was, or has agreed to become, a director or officer of the Corporation, or is or was serving, or has agreed to serve, at the request of the Corporation, as a director, officer, fiduciary, partner, trustee, member, employee or agent of, or in a similar capacity with, another corporation, partnership, joint venture, trust, limited liability company or other enterprise.

 

(c)           The term “Expenses” shall include, without limitation, attorneys’ fees, retainers, court costs, transcript costs, fees and expenses of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and other disbursements or expenses of the types customarily incurred in connection with investigations,

 

 

judicial or administrative proceedings or appeals, but shall not include the amount of judgments, fines or penalties against Indemnitee or amounts paid in settlement in connection with such matters.

 

(d)           References to “other enterprise” shall include employee benefit plans; references to “fines” shall include any excise tax assessed with respect to any employee benefit plan; references to “serving at the request of the Corporation” shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the Corporation” as referred to in this Agreement.

 

3.             Indemnity of Indemnitee.  Subject to Sections 6, 7 and 9, the Corporation shall indemnify the Indemnitee in connection with any Proceeding as to which the Indemnitee is, was or is threatened to be made a party (or is otherwise involved) by reason of the Indemnitee’s Corporate Status, to the fullest extent permitted by law (as such may be amended from time to time).  In furtherance of the foregoing and without limiting the generality thereof:

 

(a)           Indemnification in Third-Party Proceedings.  The Corporation shall indemnify the Indemnitee in accordance with the provisions of this Section 3(a) if the Indemnitee was or is a party to or threatened to be made a party to or otherwise involved in any Proceeding (other than a Proceeding by or in the right of the Corporation to procure a judgment in its favor or a Proceeding referred to in Section 6 below) by reason of the Indemnitee’s Corporate Status or by reason of any action alleged to have been taken or omitted in connection therewith, against all Expenses, judgments, fines, penalties and amounts paid in settlement actually and reasonably incurred by or on behalf of the Indemnitee in connection with such Proceeding, if the Indemnitee acted in good faith and in a manner which the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation and, with respect to any criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

 

(b)           Indemnification in Proceedings by or in the Right of the Corporation.  The Corporation shall indemnify the Indemnitee in accordance with the provisions of this Section 3(b) if the Indemnitee was or is a party to or threatened to be made a party to or otherwise involved in any Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of the Indemnitee’s Corporate Status or by reason of any action alleged to have been taken or omitted in connection therewith, against all Expenses and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred by or on behalf of the Indemnitee in connection with such Proceeding, if the Indemnitee acted in good faith and in a manner which the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, except that, if applicable law so provides, no indemnification shall be made under this Section 3(b) in respect of any claim, issue, or matter as to which the Indemnitee shall have been adjudged to be liable to the Corporation, unless, and only to the extent, that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of such liability but in view of all the

 

2

 

circumstances of the case, the Indemnitee is fairly and reasonably entitled to indemnity for such Expenses as the Court of Chancery or such other court shall deem proper.

 

4.             Indemnification of Expenses of Successful Party.  Notwithstanding any other provision of this Agreement, to the extent that the Indemnitee has been successful, on the merits or otherwise, in defense of any Proceeding or in defense of any claim, issue or matter therein (other than a Proceeding referred to in Section 6), the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by or on behalf of the Indemnitee in connection therewith.  Without limiting the foregoing, if any Proceeding or any claim, issue or matter therein is disposed of, on the merits or otherwise (including a disposition without prejudice), without (a) the disposition being adverse to the Indemnitee, (b) an adjudication that the Indemnitee was liable to the Corporation, (c) a plea of guilty or nolo contendere by the Indemnitee, (d) an adjudication that the Indemnitee did not act in good faith and in a manner the Indemnitee reasonably believed to be in or not  opposed to the best interests of the Corporation, and (e) with respect to any criminal proceeding, an adjudication that the Indemnitee had reasonable cause to believe his or her conduct was unlawful, the Indemnitee shall be considered for the purposes hereof to have been wholly successful with respect thereto.

 

5.             Indemnification for Expenses of a Witness.  To the extent that the Indemnitee is, by reason of the Indemnitee’s Corporate Status, a witness in any Proceeding to which the Indemnitee is not a party, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by or on behalf of the Indemnitee in connection therewith.

 

6.             Exceptions to Right of Indemnification.  Notwithstanding anything to the contrary in this Agreement, except as set forth in Section 10, the Corporation shall not indemnify the Indemnitee in connection with a Proceeding (or part thereof) initiated by the Indemnitee unless the initiation thereof was approved by the Board of Directors of the Corporation.  Notwithstanding anything to the contrary in this Agreement, the Corporation shall not indemnify the Indemnitee to the extent the Indemnitee is reimbursed from the proceeds of insurance, and in the event the Corporation makes any indemnification payments to the Indemnitee and the Indemnitee is subsequently reimbursed from the proceeds of insurance, the Indemnitee shall promptly refund such indemnification payments to the Corporation to the extent of such insurance reimbursement.

 

7.             Notification and Defense of Claim.  As a condition precedent to the Indemnitee’s right to be indemnified, the Indemnitee must notify the Corporation in writing as soon as practicable of any Proceeding for which indemnity will or could be sought.  With respect to any Proceeding of which the Corporation is so notified, the Corporation will be entitled to participate therein at its own expense and/or to assume the defense thereof at its own expense, with legal counsel reasonably acceptable to the Indemnitee.  After notice from the Corporation to the Indemnitee of its election so to assume such defense, the Corporation shall not be liable to the Indemnitee for any legal or other expenses subsequently incurred by the Indemnitee in connection with such Proceeding, other than as provided below in this Section 7.  The Indemnitee shall have the right to employ his or her own counsel in connection with such Proceeding, but the fees and expenses of such counsel incurred after notice from the Corporation of its assumption of the defense thereof shall be at the expense of the Indemnitee unless (a) the employment of counsel by the Indemnitee has been authorized by the Corporation, (b) counsel to

 

3

 

the Indemnitee shall have reasonably concluded that there may be a conflict of interest or position on any significant issue between the Corporation and the Indemnitee in the conduct of the defense of such Proceeding or (c) the Corporation shall not in fact have employed counsel to assume the defense of such Proceeding, in each of which cases the fees and expenses of counsel for the Indemnitee shall be at the expense of the Corporation, except as otherwise expressly provided by this Agreement, and provided that Indemnitee’s counsel shall cooperate reasonably with the Corporation’s counsel to minimize the cost of defending claims against the Corporation and the Indemnitee.  The Corporation shall not be entitled, without the consent of the Indemnitee, to assume the defense of any claim brought by or in the right of the Corporation or as to which counsel for the Indemnitee shall have reasonably made the conclusion provided for in clause (b) above.  The Corporation shall not be required to indemnify the Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its written consent.  The Corporation shall not settle any Proceeding in any manner that would impose any penalty or limitation on the Indemnitee without the Indemnitee’s written consent.  Neither the Corporation nor the Indemnitee will unreasonably withhold or delay their consent to any proposed settlement.

 

8.             Advancement of Expenses.  Subject to the provisions of Section 9, in the event that the Corporation does not assume the defense pursuant to Section 7 of any Proceeding of which the Corporation receives notice under this Agreement, any Expenses actually and reasonably incurred by or on behalf of the Indemnitee in defending such Proceeding shall be paid by the Corporation in advance of the final disposition of such Proceeding; provided, however, that the payment of such Expenses incurred by or on behalf of the Indemnitee in advance of the final disposition of such Proceeding shall be made only upon receipt of an undertaking by or on behalf of the Indemnitee to repay all amounts so advanced in the event that it shall ultimately be determined by final judicial decision from which there is no further right to appeal that the Indemnitee is not entitled to be indemnified by the Corporation as authorized in this Agreement.  Such undertaking shall be accepted without reference to the financial ability of the Indemnitee to make repayment.  Any advances and undertakings to repay pursuant to this Section 8 shall be unsecured and interest-free.

 

9.             Procedures.

 

(a)           In order to obtain indemnification or advancement of Expenses pursuant to this Agreement, the Indemnitee shall submit to the Corporation a written request, including in such request such documentation and information as is reasonably available to the Indemnitee and is reasonably necessary to determine whether and to what extent the Indemnitee is entitled to indemnification or advancement of Expenses.  Any such indemnification or advancement of Expenses shall be made promptly, and in any event within sixty (60) days after receipt by the Corporation of the written request of the Indemnitee, unless the Corporation determines within such sixty (60) day period that the Indemnitee did not meet the applicable standard of conduct.  Such determination, and any determination that advanced Expenses must be repaid to the Corporation, shall be made in each instance (i) by a majority vote of the directors of the Corporation consisting of persons who are not at that time parties to the Proceeding (“disinterested directors”), whether or not a quorum, (ii) by a committee of disinterested directors designated by a majority vote of disinterested directors, whether or not a quorum, (iii) if there are no disinterested directors, or if the disinterested directors so direct, by independent legal

 

4

 

counsel (who may, to the extent permitted by applicable law, be regular legal counsel to the Corporation) in a written opinion, or (iv) by the stockholders of the Corporation.

 

(b)           The termination of any Proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the Indemnitee did not act in good faith and in a manner that the Indemnitee reasonably believed to be in, or not opposed to, the best interests of the Corporation, and, with respect to any criminal Proceeding, had reasonable cause to believe that his or her conduct was unlawful.

 

(c)           The Indemnitee shall cooperate with the person, persons or entity making such determination with respect to the Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the Indemnitee and reasonably necessary to such determination.  Any Expenses actually and reasonably incurred by the Indemnitee in so cooperating shall be borne by the Corporation (irrespective of the determination as to the Indemnitee’s entitlement to indemnification) and the Corporation hereby indemnifies the Indemnitee therefrom.

 

10.           Remedies.  The right to indemnification or advancement of Expenses as provided by this Agreement shall be enforceable by the Indemnitee in any court of competent jurisdiction if the Corporation denies such request, in whole or in part, or if no disposition thereof is made within the applicable period referred to in Section 9.  Unless otherwise required by law, the burden of proving that indemnification or advancement of Expenses is not appropriate shall be on the Corporation.  Neither the failure of the Corporation to have made a determination prior to the commencement of such action that indemnification is proper in the circumstances because the Indemnitee has met the applicable standard of conduct, nor an actual determination by the Corporation that the Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the Indemnitee has not met the applicable standard of conduct.  The Indemnitee’s Expenses actually and reasonably incurred in connection with successfully establishing the Indemnitee’s right to indemnification, in whole or in part, in any such Proceeding shall also be indemnified by the Corporation.

 

11.           Partial Indemnification.  If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Corporation for some or a portion of the Expenses, judgments, fines, penalties or amounts paid in settlement actually and reasonably incurred by or on behalf of the Indemnitee in connection with any Proceeding but not, however, for the total amount thereof, the Corporation shall nevertheless indemnify the Indemnitee for the portion of such Expenses, judgments, fines, penalties or amounts paid in settlement to which the Indemnitee is entitled.

 

12.           Subrogation.  In the event of any payment under this Agreement, the Corporation shall be subrogated to the extent of such payment to all of the rights of recovery of the Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Corporation to bring suit to enforce such rights.

 

5

 

13.           Term of Agreement.  This Agreement shall continue until and terminate upon the later of (a) six (6) years after the date that the Indemnitee shall have ceased to serve as a director or officer of the Corporation or, at the request of the Corporation, as a director, officer, partner, trustee, member, employee or agent of another corporation, partnership, joint venture, trust, limited liability company or other enterprise or (b) the final termination of all Proceedings pending on the date set forth in clause (a) in respect of which the Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced by the Indemnitee pursuant to Section 10 of this Agreement relating thereto.

 

14.           Indemnification Hereunder Not Exclusive.  The indemnification and advancement of Expenses provided by this Agreement shall not be deemed exclusive of any other rights to which the Indemnitee may be entitled under the Certification of Incorporation, the Amended and Restated Bylaws, any other agreement, any vote of stockholders or disinterested directors, the General Corporation Law of Delaware, any other law (common or statutory), or otherwise, both as to action in the Indemnitee’s official capacity and as to action in another capacity while holding office for the Corporation.  Nothing contained in this Agreement shall be deemed to prohibit the Corporation from purchasing and maintaining insurance, at its expense, to protect itself or the Indemnitee against any expense, liability or loss incurred by it or the Indemnitee in any such capacity, or arising out of the Indemnitee’s status as such, whether or not the Indemnitee would be indemnified against such expense, liability or loss under this Agreement; provided, however, that the Corporation shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that the Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

15.           No Special Rights.  Nothing herein shall confer upon the Indemnitee any right to continue to serve as an officer or director of the Corporation for any period of time or at any particular rate of compensation.

 

16.           Savings Clause.  If this Agreement or any portion thereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify the Indemnitee as to Expenses, judgments, fines, penalties and amounts paid in settlement with respect to any Proceeding to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated and to the fullest extent permitted by applicable law.

 

17.           Counterparts.  This Agreement may be executed in any number of counterparts, each of which shall constitute the original.

 

18.           Successors and Assigns.  This Agreement shall be binding upon the Corporation and its successors and assigns and shall inure to the benefit of the estate, heirs, executors, administrators and personal representatives of the Indemnitee.

 

19.           Headings.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

 

6

 

20.           Modification and Waiver.  This Agreement may be amended from time to time to reflect changes in Delaware law or for other reasons.  No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof nor shall any such waiver constitute a continuing waiver.

 

21.           Notices.  All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been given (a) when delivered by hand or (b) if mailed by certified or registered mail with postage prepaid, on the third (3rd) day after the date on which it is so mailed:

 

(i)            if to the Indemnitee, to:

 

[                                     ]

 

(ii)           if to the Corporation, to:

 

Merrimack Pharmaceuticals, Inc.

One Kendall Square, Suite B7201

Cambridge, MA 02139

Attn: Corporate Counsel

Phone: (617) 441-1000

 

or to such other address as may have been furnished to the Indemnitee by the Corporation or to the Corporation by the Indemnitee, as the case may be.

 

22.           Applicable Law.  This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware.  The Indemnitee may elect to have the right to indemnification or reimbursement or advancement of Expenses interpreted on the basis of the applicable law in effect at the time of the occurrence of the event or events giving rise to the applicable Proceeding, to the extent permitted by law, or on the basis of the applicable law in effect at the time such indemnification or reimbursement or advancement of Expenses is sought.  Such election shall be made, by a notice in writing to the Corporation, at the time indemnification or reimbursement or advancement of Expenses is sought; provided, however, that if no such notice is given, and if the General Corporation Law of Delaware is amended, or other Delaware law is enacted, to permit further indemnification of the directors and officers, then the Indemnitee shall be indemnified to the fullest extent permitted under the General Corporation Law, as so amended, or by such other Delaware law, as so enacted.

 

23.           Enforcement.  The Corporation expressly confirms and agrees that it has entered into this Agreement in order to induce the Indemnitee to continue to serve as a director and/or officer of the Corporation, and acknowledges that the Indemnitee is relying upon this Agreement in continuing in such capacity.

 

24.           Entire Agreement.  This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein; and any prior agreement of the parties hereto in respect of

 

7

 

the subject matter contained herein is hereby terminated and cancelled.  For avoidance of doubt, the parties confirm that the foregoing does not apply to or limit the Indemnitee’s rights under Delaware law or the Corporation’s Restated Certificate of Incorporation or Amended and Restated Bylaws.

 

25.           Consent to Suit.  In the case of any dispute under or in connection with this Agreement, the Indemnitee may only bring suit against the Corporation in the Court of Chancery of the State of Delaware.  The Indemnitee hereby consents to the exclusive jurisdiction and venue of the courts of the State of Delaware, and the Indemnitee hereby waives any claim the Indemnitee may have at any time as to forum non conveniens with respect to such venue.  The Corporation shall have the right to institute any legal action arising out of or relating to this Agreement in any court of competent jurisdiction.  Any judgment entered against either of the parties in any proceeding hereunder may be entered and enforced by any court of competent jurisdiction.

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first written above.

 

 

	
 
    	
MERRIMACK   PHARMACEUTICALS, INC.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:   
    
	
 
    	
 
    	
Title:   
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
[Indemnitee]
    

 

8Exhibit 10.14

 

Sublease

 

By and Between

 

FibroGen Inc.

 

And

 

Silver Creek

 

 

Table of Contents

 

	
1.
    	
BACKGROUND
    	
1
    
	
 
    	
 
    	
 
    
	
2.
    	
SUBLEASE
    	
1
    
	
 
    	
 
    	
 
    
	
3.
    	
TERM AND TERMINATION
    	
2
    
	
 
    	
 
    	
 
    
	
4.
    	
RENT AND OTHER AMOUNTS
    	
3
    
	
 
    	
 
    	
 
    
	
5.
    	
SERVICES
    	
3
    
	
 
    	
 
    	
 
    
	
6.
    	
TAXES
    	
4
    
	
 
    	
 
    	
 
    
	
7.
    	
SECURITY DEPOSIT
    	
5
    
	
 
    	
 
    	
 
    
	
8.
    	
WARRANTY
    	
5
    
	
 
    	
 
    	
 
    
	
9.
    	
USE
    	
6
    
	
 
    	
 
    	
 
    
	
10.
    	
CONFIDENTIALITY
    	
7
    
	
 
    	
 
    	
 
    
	
11.
    	
CONDITION OF SUBLEASED PREMISES; SURRENDER
    	
7
    
	
 
    	
 
    	
 
    
	
12.
    	
SUBORDINATION
    	
8
    
	
 
    	
 
    	
 
    
	
13.
    	
INDEMNIFICATION
    	
9
    
	
 
    	
 
    	
 
    
	
14.
    	
INSURANCE
    	
9
    
	
 
    	
 
    	
 
    
	
15.
    	
MASTER LEASE
    	
11
    
	
 
    	
 
    	
 
    
	
16.
    	
ALTERATIONS AND REPAIRS
    	
13
    
	
 
    	
 
    	
 
    
	
17.
    	
ASSIGNMENT AND FURTHER SUBLETTING
    	
13
    
	
 
    	
 
    	
 
    
	
18.
    	
BROKERS
    	
13
    
	
 
    	
 
    	
 
    
	
19.
    	
SIGNS
    	
13
    
	
 
    	
 
    	
 
    
	
20.
    	
NOTICE
    	
13
    
	
 
    	
 
    	
 
    
	
21.
    	
SEVERABILITY
    	
14
    
	
 
    	
 
    	
 
    
	
22.
    	
ENTIRE AGREEMENT
    	
14
    
	
 
    	
 
    	
 
    
	
23.
    	
WAIVER
    	
14
    
	
 
    	
 
    	
 
    
	
24.
    	
HOLDING OVER
    	
15
    

 

 

	
25.
    	
BINDING EFFECT; CHOICE OF LAW
    	
15
    
	
 
    	
 
    	
 
    
	
26.
    	
FIBROGEN ACCESS
    	
15
    
	
 
    	
 
    	
 
    
	
27.
    	
SECURITY
    	
15
    
	
 
    	
 
    	
 
    
	
28.
    	
NON-SOLICITATION
    	
16
    
	
 
    	
 
    	
 
    
	
EXHIBIT A – SERVICES AND   OTHER PROVISIONS 
    	
17
    
	
 
    	
 
    	
 
    
	
EXHIBIT B – HMIS 
    	
19
    
	
 
    	
 
    	
 
    
	
EXHIBIT C – THE INJURY AND   ILLNESS PREVENTION PROGRAM 
    	
20
    
	
 
    	
 
    	
 
    
	
EXHIBIT D – MASTER LEASE   (REDACTED) 
    	
21
    
					

 

 

SUBLEASE

 

This SUBLEASE (“Sublease”) is effective as of August 6, 2010 (“Effective Date”), by and between FibroGen, Inc., a Delaware Corporation (“FibroGen”), and Silver Creek (“Subtenant”).

 

1.             BACKGROUND

 

1.1           Under a lease dated September 22, 2006 (“Master Lease”) by and between X-4 Dolphin LLC, on behalf of Shorenstein Properties, LLC (“Master Lessor”) and FibroGen, a redacted copy of which is attached hereto and incorporated herein as Exhibit D, Master Lessor has Subleased to FibroGen a building located at 409 Illinois Street, San Francisco, California containing approximately 234,000 rentable square feet (“409 Building”) for a period commencing upon the completion of the Building, as defined in the Master Lease, and expiring on the fifteen (15) year anniversary thereof.

 

1.2           Subtenant wishes to sublease from FibroGen and FibroGen wishes to sublet to Subtenant certain office and laboratory space located in the 409 Building (the Subleased Premises) as defined in Paragraph 2.1 below.

 

1.3           Subtenant wishes to acquire services associated with the use of the Subleased Premises, and FibroGen is willing to provide such services as specified herein.

 

THE PARTIES AGREE AS FOLLOWS:

 

2.             SUBLEASE

 

2.1           Conditioned upon receipt of Master Lessor’s written consent, FibroGen hereby subleases to Subtenant and Subtenant hereby takes from FibroGen certain real property as described below (the “Subleased Premises”) comprising approximately a total grossed-up footprint equaling Seven Hundred and Fifty-six (756) square feet as follows:

 

a)             In the laboratory area #5115; office area #5202 and open area #5221.

 

b)            The Sublease Premises may be increased upon the mutual agreement of the parties hereto in the form of a signed amendment to this Sublease.  However, it is expressly understood that neither party hereto is obligated to enter into such an amendment.

 

2.2           Subtenant shall also have the non-exclusive right to use, in common with other Subtenants in the Building, any and all of the following areas which may be appurtenant to the Premises: common entrances, lobbies, elevators, stairways, corridors, and access

 

 

1

 

ways, public restrooms, FibroGen Gym (subject to payment as specified in Exhibit A), Cafe, and common walkways and sidewalks necessary for access to the Premises.

 

3.             TERM AND TERMINATION

 

3.1           The term (“Term”) of this Sublease will commence on September 1, 2010 (“Sublease Commencement Date”).

 

3.2           This Sublease will expire on:

 

a)             September 1, 2011 (“Expiration Date”), unless Subtenant requests for an extension to the Sublease for another six (6) months in writing to FibroGen no later than thirty (30) days in advance of the Expiration Date.

 

3.3           It is expressly understood, notwithstanding the terms stated above, that either party hereto may terminate this Sublease for cause pursuant to Paragraphs 9.6 and 15.2 of this Sublease.

 

3.4           Either party hereto may terminate this Sublease at any time by giving sixty (60) days’ written notice to the other.

 

3.5           Notwithstanding any terms contained herein, it is Subtenant’s sole responsibility to place the Premises in the surrender condition required by FibroGen and Master Lessor not later than the Expiration Date, including, but not limited to, covering all costs of decertification and decommissioning (if required).

 

3.6           On the Sublease Commencement Date, FibroGen shall deliver possession of the Premises to Subtenant in the condition required by Paragraph 11.2.  No rent shall accrue under this Sublease, nor shall Subtenant have any obligation to perform the covenants or observe the conditions herein contained until the Premises have been so delivered.  If FibroGen’s ability to deliver possession by the date as set forth in this provision is delayed as a result of any of the following causes, the date for delivery shall be postponed without penalty to FibroGen for a period of time equivalent to the period caused by such delay:

 

a)                                      acts of Subtenant, its agents, or employees;

 

b)                                     acts of God which FibroGen could not reasonably have foreseen or guarded against;

 

c)                                      any strikes, boycotts or like obstructive actions by employees or labor organizations and which are beyond the control of FibroGen and which cannot be reasonably overcome; or

 

d)                                     restrictive regulations by a governmental agency.

 

2

 

4.             RENT AND OTHER AMOUNTS.

 

4.1           Subtenant shall pay a monthly rent (“Rent”) to FibroGen for the Subleased Premises according to the following schedule:

 

	
Months
    	
 
    	
Rent/Sq.Ft./Mo.
    	
 
    	
Total Sq. Ft.
    	
 
    	
Amount/Mo.
    	
 
    
	
September 2010 –   Expiration Date
    	
 
    	
$
    	
6.80
    	
 
    	
756
    	
 
    	
$
    	
5,174.80
    	
 
    
										

 

Rent shall cover the following expenses:

 

a)             Operating expenses comprising property tax and insurance, normal utility charges, exterior building maintenance, maintenance of mechanical systems that are currently in place, normal recurring building maintenance, janitorial service according to FibroGen’s generally accepted office and laboratory cleaning standards, normal office and laboratory waste removal, a pro-rata share (based on the area actually subleased by Subtenant at the time of the emergency) of the emergency electrical backup generation services available to the 409 Building, and security systems (including issuance of up to 5 security entrance cards).

 

b)            Those services specified in Paragraph 5.1 below.

 

4.2           All Rent shall be payable without deduction or offset in advance on the first day of each month during the Term provided however, the first month’s Rent for the Subleased Premises will be paid to FibroGen no later than seven (7) days prior to the Sublease Commencement Date.  Rent for any period during the term hereof which is for less than one month shall be a pro rata portion of the monthly installment.  Rent shall be payable to FibroGen at the address stated herein or at such other address as FibroGen may from time to time designate in writing.

 

4.3           Except as expressly herein provided, any amount due FibroGen but not paid when due shall bear interest at the lesser of ten percent (10%) per annum or the maximum rate then allowable by law from the date due.  Payment of such interest shall not excuse or cure any default by Subtenant under this Sublease, provided, however, that interest shall not be payable on late charges incurred by Subtenant nor on any amounts upon which late charges are paid by Subtenant.

 

5.             SERVICES

 

5.1           Included lab services are limited to the systems that are in place on the Sublease Commencement Date to supply de-ionized water (DI) water, house vacuum, and compressed air.  It is expressly understood that no gases (other than compressed air) will be supplied to the Subleased Premises by FibroGen.  However, FibroGen will (at no cost to Subtenant) install wall mounts to secure laboratory gas cylinders in the Subleased Premises subject to the restrictions contained in Paragraph 9.5.  FibroGen represents that

 

3

 

the DI water, house vacuum and compressed air are, and shall be, maintained by FibroGen in good working order.

 

a)             Normal business hours for services provided by FibroGen employees or agents (such as receptionist, loading, and unloading) shall be from 8 am to 5 pm, Monday through Friday, FibroGen holidays and other infrequent dates and times reasonably designated by FibroGen excepted.  No such services shall be available during nights, weekends, and FibroGen holidays.

 

5.2           Services and utilities not specified in Paragraph 5.1 above, shall be furnished and the cost borne as outlined in Exhibit A.  If any such services are not separately metered to Subtenant, Subtenant shall pay a reasonable proportion to be determined by FibroGen of all charges jointly metered with other premises.  In the event of failure by FibroGen to furnish, in a satisfactory manner, any of the services and utilities to the Premises for which FibroGen is responsible, Subtenant may furnish the same if FibroGen has not undertaken to correct such failure within five (5) days after written notice, and, in addition to any other remedy Subtenant may have, may deduct the amount thereof, including Subtenant’s service costs, from rent or other remuneration due FibroGen hereunder.

 

5.3           Charges for all services provided hereunder shall be invoiced on the fifteenth (15th) day of each month immediately following the provision of the service and shall be due and payable along with the next rent payment due after receipt of the invoice for such services.

 

5.4           Exhibit A may be amended in a signed writing to include new service or remove existing services as mutually acceptable to the parties hereto.

 

6.             TAXES

 

6.1           FibroGen specifically calls to Subtenant’s attention the fact that this Sublease may create a possessory interest subject to property taxation, and Subtenant may be subject to property tax levied on such interest.  Subtenant alone shall pay such tax.  If the right is given to pay any of the taxes, assessments or other impositions which Subtenant is herein obligated to pay either in one sum or in installments, Subtenant may elect either mode of payment.

 

6.2           Subtenant shall pay prior to delinquency all taxes assessed against and levied upon trade fixtures, furnishings, equipment and all other personal property of Subtenant contained in the Premises or elsewhere.  Subtenant shall cause said trade fixtures, furnishings, equipment and all other personal property to be assessed and billed separately from the real property of FibroGen.

 

4

 

7.             SECURITY DEPOSIT

 

7.1           On or before the date of final signature by both parties hereto, Subtenant shall deposit with FibroGen a sum equal to one hundred percent (100%) of the first month’s Rent; and on or before the Sublease Commencement Date, Subtenant shall deposit with FibroGen an additional sum equal to two hundred percent (200%) of the first month’s Rent both sums as security for the full and faithful performance of each provision of this Sublease.

 

7.2           Subtenant shall provide a properly completed, signed and dated IRS Form W-9 or Form W-8BEN (as applicable, the “IRS W8/9 Form”) to FibroGen.

 

7.3           If Subtenant defaults with respect to any provision of this Sublease, including, but not limited to, the provisions relating to the payment of Rent or other charges, FibroGen may use, apply or retain all or any part of said deposit for the payment of Rent or other charges in default; or for the payment of any other amount which FibroGen may spend or become obligated to spend by reason of Subtenant’s default.  If any portion of said deposit is so used or applied, Subtenant shall, within ten (10) days after written demand therefore, deposit cash with FibroGen in an amount sufficient to restore said deposit to the full amount hereinabove stated, and Subtenant’s failure to do so shall be a material breach of this Sublease.  If Subtenant fully and faithfully performs every provision required by this Sublease, said deposit, or so much thereof as has not theretofore been applied or credited by FibroGen shall be returned to Subtenant (or, at FibroGen’s option, to the last assignee of Subtenant’s interest hereunder) at the expiration of the term hereof.  The making by Subtenant of such deposit, or the application thereof by FibroGen in the manner hereinabove provided, shall not constitute nor be construed as a limitation upon the exercise by FibroGen of any other rights or remedies provided to FibroGen under the terms of this Sublease in the event of Subtenant’s default.  In the event FibroGen sells or assigns FibroGen’s interest in the 409 Building, FibroGen may assign said deposit to the purchaser of FibroGen’s interest in the demised premises without liability to Subtenant.  FibroGen’s obligations with respect to the deposit are those of a debtor and not a trustee.  FibroGen may maintain the deposit separate and apart from FibroGen’s general funds or can commingle the deposit with FibroGen’s general and other funds.

 

8.             WARRANTY

 

8.1           FibroGen warrants that the Subleased Premises are non-toxic and asbestos free to the best of its knowledge subject to the conditions set forth in the Lease between the Master Lessor and FibroGen.

 

8.2           FibroGen further warrants that all laboratory space shall remain as equipped at the date of signature of the Sublease with case-goods and hoods.  It is expressly understood that equipment specifically owned and used by FibroGen is not included hereunder.

 

5

 

8.3           Except for the warranty provided in Paragraph 8.1 and 8.2 above, the Subleased Premises and any cubicles, furniture, equipment, and fixtures provided hereunder are provided on an “as-is” basis WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY EXPRESS OR IMPLIED.

 

9.             USE

 

9.1           Subtenant shall use the Subleased Premises for the purpose of laboratory research and development, and general office purposes consistent with the requirements and limitations set forth in the Master Lease and for no other purpose without the prior written consent of Master Lessor and FibroGen.  In no case shall pets be allowed inside of the 409 Building.

 

9.2           Use of radioactive materials in the Subleased Premises is expressly prohibited without FibroGen’s express written consent.

 

9.3           In addition to all duties required under this Sublease, it is expressly understood that Subtenant shall be responsible for complying with the provisions of the Master Lease (including Article 10 [Compliance with Laws and Regulations] therein) incorporated herein by Section 15.1 relating to hazardous materials.  In no event shall Subtenant cause the classification of the 409 Building to be changed from its present classification (Level B).

 

9.4           Subtenant shall comply with all applicable federal, state and local regulations.  Subtenant shall additionally comply with as all applicable policies and procedures of FibroGen, including but not limited to the FibroGen Safety Program and the Injury and Illness Prevention Program (“IIPP”) appearing in Exhibit C.  It is expressly understood that all chemical use by Subtenant shall be in compliance with the Hazard Materials Identification System (HMIS) appearing in Exhibit B.

 

9.5           Subtenant shall obtain FibroGen’s express written authorization prior to using any gasses not listed below:

 

a)             CO2, CH4, Nitrogen, O2, Compressed Air, Liquid Nitrogen

 

9.6           Any breach of this Article 9, shall give FibroGen the right to terminate this Sublease upon fifteen (15) days written notice for any breach remaining uncured for a period of five (5) days from the date of FibroGen’s initial written notice of Subtenant’s breach.

 

6

 

10.           CONFIDENTIALITY

 

10.1         Each party hereto acknowledges that it shares space with the other party and may come into contact with information in various forms (including visual, oral, written, graphic, or electronic) that may be deemed to be confidential and proprietary.

 

10.2         Each party hereto shall treat the Confidential Information of the other as proprietary and confidential and hold it in strict trust and confidence using at least the same degree of care as it uses to protect its own most highly confidential information, but in no event, using less than a reasonable degree of care.  The receiving party shall NOT:

 

a)                                      permit access to or disclose the Confidential Information to any unauthorized third party;

 

b)                                     reverse engineer or reverse compile the Confidential Information;

 

c)                                      make any commercial use of the Confidential Information;

 

d)                                     use any Confidential Information to support any patent application or related filing; or

 

e)                                      use Confidential Information for any purpose or in any manner which would constitute a violation of any laws or regulations, including without limitation the export control laws of the United States.

 

10.3         Each party hereto shall advise its officers, employees, independent contractors and business invitees who might have access to Confidential Information of the confidential nature thereof.

 

10.4         The knowledge of Confidential Information by one party shall not constitute any grant, option, or license to the other in any intellectual property rights or interest in the Confidential Information now or hereinafter.

 

10.5         The parties hereto agree that for any violation of any provision of this Section 10 (Confidentiality), the aggrieved party shall be entitled, in addition to any other remedies it may have and without the need to post a bond, to specific performance, injunctions or other appropriate remedies it may have for any such violation by the non-aggrieved party.

 

11.           CONDITION OF SUBLEASED PREMISES; SURRENDER.

 

11.1         Subtenant shall accept the Subleased Premises in their “as is” condition.

 

11.2         FibroGen shall deliver the Premises to Subtenant clean and free of debris on the Sublease Commencement Date and FibroGen further warrants to Subtenant that the plumbing, lighting, air conditioning, and heating systems, in the Premises shall be in good operating condition on the Sublease Commencement Date.  If this warranty has been

 

7

 

violated, then FibroGen shall, after receipt of written notice from Subtenant setting forth with specificity the nature of the violation, promptly, at FibroGen’s sole cost, rectify such violation.  Subtenant’s failure to give such written notice to FibroGen within thirty (30) days after the Sublease Commencement Date shall cause the conclusive presumption that FibroGen has complied with all of FibroGen’s obligations hereunder.

 

11.3         Except as otherwise provided in this Sublease, Subtenant hereby accepts the Premises in the condition existing as of the Sublease Commencement Date or the date that Subtenant takes possession of the Premises, whichever is earlier, subject to all applicable zoning, municipal, county and state laws, ordinances and regulations governing and regulating the use of the Premises, and any covenants or restrictions of record, and accepts this Sublease subject thereto and to all matters disclosed thereby and by any exhibits attached hereto.  Subtenant acknowledges that neither FibroGen nor any agent of FibroGen has made any representation or warranty as to the present or future suitability of the Premises for the conduct of Subtenant’s business.

 

11.4         Within ten (10) days of the Sublease Commencement Date of this Sublease, Subtenant shall provide FibroGen with a list (“Damage List”) of any defects or damage present in the Subleased Premises, and on the cubicles, furniture, equipment, or fixtures as reasonably observable by Subtenant.  FibroGen shall have ten (10) business days to object to any defects or damage present on the Damage List.  After the ten day period after Sublease Commencement Date, Subtenant shall be precluded from claiming any defect or damage was present in the Subleased Premises or on the furniture or cubicles if such defect or damage was not present on the Damage List prior to the Sublease Commencement Date.

 

11.5         Upon the expiration or termination date of this Sublease pursuant to Article 3.2, Subtenant shall surrender to FibroGen the Subleased Premises and any and all cubicles, furniture, equipment and fixtures supplied by FibroGen in the same condition and repair as received (ordinary wear and tear, damage, and casualty that Subtenant under the Master Lease has no obligation to restore or repair excepted), broom-clean, and otherwise in the condition required by the Master Lease and shall repair any damage to the Subleased Premises occasioned by the removal of Subtenant’s fixtures, furnishings, and equipment.

 

11.6         Upon surrender of the Subleased Premises, Subtenant shall warrant that the Subleased Premises are non-toxic and asbestos-free to the best of its knowledge to the extent they were at the time Subtenant took occupancy.

 

12.           SUBORDINATION.

 

12.1         This Sublease is subject and subordinate to the Master Lease.

 

8

 

13.           INDEMNIFICATION.

 

13.1         FibroGen shall indemnify, defend and hold harmless Subtenant, its officers, partners, agents, and employees from and against any claims, damages, costs, expenses, or liabilities (collectively “Claims”) arising out of or in any way connected with this Sublease including, without limitation, Claims for loss or damage to any property, or for death or injury to any person or persons, but only in proportion to and to the extent that such Claims arise from the negligent or wrongful acts or omissions of FibroGen, its officers, agents, or employees.

 

13.2         Subtenant shall indemnify, defend and hold harmless FibroGen, its officers, agents, and employees from and against any Claims arising out of or in any way connected with this Sublease including, without limitation, Claims for loss or damage to any property or for death or injury to any person or persons, but only in proportion to and to the extent that such Claims arise from the negligent or wrongful acts or omissions of Subtenant, its officers, partners, agents, or employees.

 

13.3         Subtenant shall further indemnify FibroGen and the Master Lessor as provided in Subparagraph 14.4 of the Master Lease.  The provisions that Subparagraph are hereby incorporated herein by reference subject to the following understandings:

 

a)                                      The term “Tenant” as used in Subparagraph 14.4 of the Master Lease shall refer to Subtenant.

 

b)                                     The term “Landlord” as used in Subparagraph 14.4 of the Master Lease shall refer to both FibroGen and the Master Lessor.

 

13.4         Intellectual Property Rights Indemnification.  Subtenant acknowledges the shared nature of the 409 Building and the fact that various business entities and FibroGen’s agents and employees may occupy portions of the 409 Building during the term of this Sublease.  It is expressly understood that FibroGen can not guarantee Subtenant’s privacy and protect its trade secrets within the 409 Building.  With respect to any and all claims arising out of or connected to a breach of Subtenant’s privacy and protection of its trade secrets associated with Subtenant’s intellectual property rights, Subtenant hereby agrees to indemnify and hold FibroGen harmless against said claims.

 

14.           INSURANCE.

 

14.1         Subtenant, at its sole cost and expense, shall insure its activities in connection with this Sublease and obtain, keep in force and maintain insurance as follows:

 

a)             Commercial Form General Liability Insurance (contractual liability included) with minimum limits as follows:

 

i)                                         Each Occurrence $ 1,000,000

 

9

 

ii)                                      Products/Completed Operations Aggregate $ N/A

 

iii)                                   Personal and Advertising Injury $ 1,000,000

 

iv)                                  General Aggregate $ 2,000,000

 

If the above insurance is written on a claims-made form, it shall continue for three (3) years following termination of this Sublease.  The insurance shall have a retroactive date of placement prior to or coinciding with the Sublease Commencement Date.

 

b)                                     Business Automobile Liability Insurance for owned, scheduled, non-owned, or hired automobiles with a combined single limit of not less than one million dollars ($ 1,000,000) per occurrence.

 

c)                                      Property, Fire and Extended Coverage Insurance in an amount sufficient to reimburse Subtenant for all of its equipment, trade fixtures, inventory, fixtures and other personal property located on or in the Premises including Subleasehold improvements hereinafter constructed or installed.

 

d)                                     Workers’ Compensation as required by California law.

 

e)                                      Such other insurance in such amounts which from time to time may be reasonably required by the mutual consent of Subtenant and FibroGen against other insurable risks relating to performance.

 

14.2         The coverages referred to under 14.1a) and 14.1b) above shall include FibroGen  as an additional insured.  Such a provision shall apply only in proportion to and to the extent of the negligent acts or omissions of Subtenant, its officers, partners, agents, and employees.

 

14.3         Subtenant, upon the execution of this Sublease, shall furnish FibroGen with certificates of insurance evidencing compliance with all requirements.  Certificates shall provide for thirty (30) days (ten [10] days for non-payment of premium) advance written notice to FibroGen of any material modification, change or cancellation of any of the above insurance coverages.

 

14.4         The coverages required herein shall not limit the liability of Subtenant.

 

14.5         Waivers of Subrogation.  Notwithstanding the provisions of Article 13, Subtenant hereby waives any right of recovery against FibroGen due to loss of or damage to the property of Subtenant when such loss of or damage to property arises out of the acts of God or any of the property perils included in the classification of fire, extended perils (“all risk” as such term is used in the insurance industry) whether or not such perils have been insured, self-insured or non-insured.

 

14.6         Exemption of FibroGen from Liability.  Notwithstanding the terms of Article 13, Subtenant hereby agrees that FibroGen shall not be liable for injury to Subtenant’s

 

10

 

business or any loss of income therefrom or for damage to the goods, wares, merchandise or other property of Subtenant, Subtenant’s employees, invitees, customers, or any other person in or about the Premises, nor shall FibroGen be liable for injury to the person of Subtenant, Subtenant’s employees, agents or contractors, as a result of any condition of the Premises or the 409 Building, whether such damage or injury is caused by or results from fire, steam, electricity, gas, water or rain, or from the breakage, leakage, obstruction or other defects of pipes, sprinklers, wires, appliances, plumbing, air conditioning or lighting fixtures, or from any other cause in or about the Premises, whether the said damage or injury results from conditions arising in the Premises or in other portions of the 409 Building, or from other sources or places and regardless of whether the cause of such damage or injury or the means of repairing the same is inaccessible to Subtenant.  FibroGen shall not be liable for any damages arising from any act or neglect of any other Subtenant, if any, of the 409 Building.

 

15.           MASTER LEASE

 

15.1         Except for:

 

·                  Paragraph 14.4 of the Master Lease that is incorporated by reference hereinabove;

 

·                  the following Paragraphs of the Master Lease (which are not incorporated into this Sublease): 1.12, 1.15, 2.6, 3.1, 3.4, 11.1, 13.3, 13.4, 23.1, 24.1(d), 27.1, 35.2, 35.24(a), and 35.24(b); and

 

·                  the following Articles of the Master Lease (which are not incorporated into this Sublease): 4, 5, 8, 12, 15, 16, 18, 19, 21, 33, and 34;

 

and to the extent not otherwise inconsistent with the agreements and understandings expressed in this Sublease or applicable only to the original parties to the Master Lease, the provisions of the Master Lease are hereby incorporated herein by reference subject to the following understandings:

 

a)                                      Subtenant shall pay any real estate taxes, personal property taxes, and property insurance on its alterations, trade fixtures, and personal property that are not included in the Rent.

 

b)                                     The term “Tenant” as used therein shall refer to Subtenant.

 

c)                                      The term “Landlord” as used therein shall refer to FibroGen.

 

d)                                     FibroGen shall not be obligated to exercise any options provided in the Master Lease.

 

e)                                      All of Master Lessor’s rights under the Master Lease shall inure to the benefit of FibroGen as well as to Master Lessor.

 

11

 

15.2         Each party hereto, respectively, shall perform and comply with the provisions of the Master Lease relating to Master Lessor’s and Subtenant’s obligations.  Subtenant hereby assumes and agrees to perform all of the obligations of Subtenant under the Master Lease accruing or arising during the term of this Sublease in the manner and within the time required under the Master Lease provided, however, the obligation of Subtenant hereunder shall be interpreted to apply only to the extent to which the obligations of Subtenant under the Master Lease are applicable or allocable to the Subleased Premises.  Subtenant further covenants that Subtenant will neither commit nor permit to be committed by any third party, any act or omission which would violate any term or condition of the Master Lease, or be the cause for termination of the Master Lease by Master Lessor.  In any case where Master Lessor has the right to declare a default under the Master Lease, said right shall inure to the benefit of FibroGen.

 

15.3         FibroGen shall have all of the rights and remedies afforded Master Lessor under the Master Lease.  In addition to exercising any other rights or remedies afforded to the Master Lessor under the Master Lease, FibroGen shall have the right (but not the obligation) to:

 

a)                                      cure any such breach or default by Subtenant, with Subtenant to be obligated to reimburse FibroGen immediately upon demand for all costs (including costs of settlements, defense, court costs and attorneys’ fees) which FibroGen may incur in effecting the cure of such breach or default;

 

b)                                     reenter and retake possession of the Subleased Premises and immediately terminate this Sublease and Subtenant’s interest in the Subleased Premises; and

 

c)                                      have any and all rights and remedies now or hereafter afforded a landlord under applicable law, including but not limited to: (A) all of the remedies afforded under Section 1951.2 of the California Civil Code (or any successor statute or similar applicable statute), specifically including Subsection (a)(3) thereof with respect to recovering the worth at the time of award of the amount by which the unpaid Rent for the balance of the term of this Sublease after the time of award exceeds the amount of such rental loss that Subtenant proves could be reasonably avoided, and in respect to this paragraph, it is expressly agreed that an interest rate of ten percent (10%) per annum is to be used in computing the “worth at the time of award” with respect to the damages recoverable under Subsections (a)(1) and (a)(2) thereof, and (B) notwithstanding any abandonment of the Subleased Premises by Subtenant, the remedy afforded under Section 1951.4 of the California Civil Code (or any successor statute or similar applicable statute) of continuing the Sublease in effect and recovering from Subtenant, the Rent and other amounts payable hereunder as they become due under this Sublease.

 

15.4         Subtenant and FibroGen each represent and warrant that they have read and are familiar with the terms and conditions of the Master Lease.

 

12

 

16.           ALTERATIONS AND REPAIRS

 

16.1         Subtenant shall make no alterations to the Premises without the prior written authorization of FibroGen.

 

17.           ASSIGNMENT AND FURTHER SUBLETTING

 

17.1         Subject to Master Lessor and FibroGen’s express written consent, Subtenant shall have the right to assign all or any portion of its interest under this Sublease or sublet all or any portion of the Subleased Premises to any third party, parent, subsidiary or affiliate of Subtenant; any party which results from any merger or consolidation of Subtenant; or any party which acquires all or substantially all the assets or stock of Subtenant.

 

17.2         Other than expressly permitted in Paragraph 17.1 above, Subtenant shall have no right to allow any other party to sublease, assign, or otherwise use the facilities referenced hereunder for any purpose without FibroGen’s express written authorization.

 

18.           BROKERS

 

18.1         FibroGen and Subtenant each represents and warrants to the other that it has not engaged any broker, finder or other person who would be entitled to any commission or fees in respect of the negotiation, execution or delivery of this Sublease and shall indemnify and hold harmless the other against any loss, cost, liability or expense incurred by the indemnified party as a result of any claim asserted by any such broker, finder or other person on the basis of any arrangements or agreements made or alleged to have been made by or on behalf of indemnifying party.

 

19.           SIGNS

 

19.1         FibroGen shall add Subtenant’s name to a placard located on in the reception area of the main lobby.  Aside from the foregoing, Subtenant shall not have any other signs on the Subleased Premises or the 409 Building other than signs within the Subleased Premises for Subtenant’s internal use and convenience.

 

20.           NOTICE

 

20.1         Any notices or demands to be given pursuant to the Master Lease or this Sublease shall be in writing and shall be delivered personally or sent by registered or certified mail, return receipt requested, with all postage and fees prepaid, to FibroGen or Subtenant, respectively, at the following addresses, or at such other address as such party shall designate by written notice to the other party.  Such addresses are:

 

13

 

	
FibroGen:
    	
FibroGen, Inc.
    
	
 
    	
409   Illinois St.
    
	
 
    	
San   Francisco, CA 94158
    
	
 
    	
Attention:   CFO
    

 

	
Subtenant:
    	
Silver   Creek
    
	
 
    	
409   Illinois St.
    
	
 
    	
San   Francisco, CA 94158
    
	
 
    	
Attention:   President
    

 

Personal delivery may be accomplished by means of commercial “overnight” or “express” delivery services providing for written record or delivery, or otherwise.  Such notices shall be deemed to have been received and to be effective for all purposes upon receipt or refusal to accept delivery at such address as indicated on the return receipt or other record of delivery, or (if earlier) on the second business day after being mailed in accordance with the requirements of this paragraph.

 

21.           SEVERABILITY

 

21.1         The invalidity of any provision of this Sublease as determined by a court of competent jurisdiction, shall in no way affect the validity of any other provision hereof.

 

22.           ENTIRE AGREEMENT

 

22.1         Attached hereto and incorporated herein are Exhibits A, B, C, and D which constitute part of this Sublease.

 

22.2         There are no oral agreements or understandings between the parties hereto affecting this Sublease.  This Sublease cannot be changed or terminated orally but only by an agreement in writing signed by the party against whom enforcement or any waiver, change, modification or discharge is sought.

 

23.           WAIVER

 

23.1         No waiver by FibroGen of any provision hereof shall be deemed a waiver of any other provision hereof or of any subsequent breach by Subtenant of the same or any other provision.  FibroGen’s consent to, or approval of, any act shall not be deemed to render unnecessary the obtaining of FibroGen’s consent to or approval of any subsequent act by Subtenant.  The acceptance of rent hereunder by FibroGen shall not be a waiver of any preceding breach by Subtenant of any provision hereof, other than the failure of

 

14

 

Subtenant to pay the particular rent so accepted, regardless of FibroGen’s knowledge of such preceding breach at the time of acceptance of such rent.

 

24.           HOLDING OVER

 

24.1         If Subtenant, with FibroGen’s consent, remains in possession of the Premises or any part thereof after the expiration of the term hereof, such occupancy shall be a tenancy from month to month upon all the provisions of this Sublease pertaining to the obligations of Subtenant, with the exception of rent which shall be at one hundred twenty-five percent (125%) of the then current rent, but all options and rights of first refusal, if any, granted upon the terms of this Sublease shall be deemed terminated and be of no further effect during said month to month tenancy.

 

25.           BINDING EFFECT; CHOICE OF LAW

 

25.1         Subject to any provisions hereof restricting assignment or subletting by Subtenant, this Sublease shall bind the parties, their personal representatives, successors and assigns.  This Sublease shall be governed by the laws of the State of California, and any legal dispute arising hereunder shall be adjudicated in a court of law located in San Francisco, California.

 

26.           FIBROGEN ACCESS

 

26.1         FibroGen and FibroGen’s agents shall have the right to enter the Premises at reasonable times, for the purpose of making alterations, repairs, improvements or additions to the Premises or to the Building as FibroGen may deem necessary or desirable.  FibroGen and FibroGen’s agents shall provide Subtenant with one (1) regular business day notice prior to entry of the Premises for the purpose of inspecting the same, showing the same to prospective purchasers, lenders, or lessees.  Any entry by FibroGen and FibroGen’s agents shall not impair Subtenant’s operations more than reasonably necessary, and shall comply with Subtenant’s reasonable security measures.  Except in case of an emergency, FibroGen shall not enter the Premises (except for the performance of regular janitorial service) unless accompanied by a representative of Subtenant.

 

27.           SECURITY

 

27.1         Subtenant assumes all responsibility for the protection of Subtenant, its agents and invitees from acts of third parties.  FibroGen shall provide Subtenant with keys to the Premises, Building and the Incubator Lab at FibroGen’s cost and expense.

 

15

 

28.           NON-SOLICITATION

 

28.1         During the Term of this Sublease and for a period of six (6) months following the termination or expiration thereof, neither party hereto shall directly or indirectly induce or solicit any employee of the other party to leave their employment.

 

IN WITNESS WHEREOF, the parties hereto have executed this Sublease effective as of the day and year first above written.

 

	
 
    	
FIBROGEN, INC.
    
	
 
    	
 
    
	
 
    	
JENNIFER   KAJISA
    
	
 
    	
Name
    
	
 
    	
 
    
	
 
    	
/s/   Jennifer S. Kajisa
    
	
 
    	
Signature
    
	
 
    	
 
    
	
 
    	
SENIOR   MANAGER, FINANCIAL REPORTING
    
	
 
    	
Title
    
	
 
    	
 
    
	
 
    	
8/12/10
    
	
 
    	
Date
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
SILVER   CREEK
    
	
 
    	
 
    
	
 
    	
ULRIK   NIELSEN
    
	
 
    	
Name
    
	
 
    	
 
    
	
 
    	
/s/   Ulrik Nielsen
    
	
 
    	
Signature
    
	
 
    	
 
    
	
 
    	
PRESIDENT
    
	
 
    	
Title
    
	
 
    	
 
    
	
 
    	
8/20/10
    
	
 
    	
Date
    

 

16

 

EXHIBIT A – SERVICES AND OTHER PROVISIONS

 

Service Charges

 

for

 

Premises Located at

 

409 Illinois Street, San Francisco, California 94158

 

 

Silver Creek - Service Charges for
 409 Illinois Street, San Francisco, CA 94158

 

	
Mail/Receiving/Receptionist Support
    	
 
    	
N/A Included in rent
    
	
 
    	
 
    	
 
    
	
Security Guard Services
    	
 
    	
N/A  

Included in Rent
    
	
 
    	
 
    	
 
    
	
Security  
   Cost/Security Card
    	
 
    	
 

Initial 5 no charge 

$25 each thereafter
    
	
 
    	
 
    	
 
    
	
Telecommunications/Data Support  
   Infrastructure Charge
    	
 
    	
 

$70/month
    
	
 
    	
 
    	
 
    
	
Cost/month/phone
    	
 
    	
$10.33 each + monthly 

Usage charges
    
	
 
    	
 
    	
 
    
	
Installation charges (phone & voicemail)
    	
 
    	
$150 (one-time charge)
    
	
 
    	
 
    	
 
    
	
Custom IT Services (pay as you go)
    	
 
    	
 
    
	
a. Helpdesk
    	
 
    	
$60/hour
    
	
b. Network Configuration
    	
 
    	
$120/hour
    
	
c. Server set-up
    	
 
    	
$150/hour
    
	
d. Secure wireless network
    	
 
    	
 
    
	
– Wireless internet only
    	
 
    	
$70/month flat rate
    
	
– Wireless internet plus internal network access
    	
 
    	
$70/month, plus a $480 

one-time set up fee
    
	
e. Secure Remote Access (via Cisco VPN software)
    	
 
    	
$70/month/user account 

Plus $480 one-time set up fee
    
	
f. Data Center Rack Space (1U = 1.75 inches of   vertical rack space)
    	
 
    	
$120/1U/month, plus $240 

one-time set up fee
    
	
*Any   additional data drops or outlets beyond what is provided shall be charged   separately
    	
 
    	
 
    
	
 
    	
 
    	
TBD
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
$/Run
    
	
Glasswash/Autoclave  

Total Cost/run-glasswash/dryer
    	
 
    	
$40.00
    
	
 
    	
 
    	
 
    
	
Autoclave 

Glasswash/dryer and autoclave
    	
 
    	
$40.00 

$60.00
    
	
 
    	
 
    	
 
    
	
Parking  

Parking charge per day/ per vehicle 

*Can be included as a corporate cost or paid   directly by employees
    	
 
    	
 

$24/day or $235/month
    
	
 
    	
 
    	
 
    
	
FibroGym - Workout   Room (located on the 1st Floor)
    	
 
    	
$10/person/month
    
	
 
    	
 
    	
 
    
	
Conference Room
   With exception of conference rooms to be shared by all micro companies,   charges for use
   of major conference rooms, will be based on length of time needed
    	
 
    	
 
    

 

 

EXHIBIT B – HMIS

 

Fire Code Permit Amounts

 

For

 

Hazardous Materials

 

As allowed on Each Floor of the

 

409 Building

 

 

EXHIBIT C – THE INJURY AND ILLNESS PREVENTION PROGRAM

 

The

 

Injury and Illness

 

Prevention Program

 

September 2008

 

 

EXHIBIT D – MASTER LEASE (REDACTED)

 

Redacted copy of

 

The Lease Agreement

 

Between

 

Master Lessor

 

And

 

FibroGen

 

September 22, 2006

 

 

AMENDMENT NO. 1 TO SUBLEASE

 

THIS AMENDMENT NO. 1 (the “First Amendment”) is effective as of February 1, 2011 (the “First Amendment Effective Date”) by and between Silver Creek Pharmaceuticals (“Subtenant”) and FibroGen, Inc. (“FibroGen”).  This First Amendment amends the Sublease entered into by and between Subtenant and FibroGen on August 6, 2010 (the “Sublease”).  Subtenant and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”.  The Sublease and this First Amendment are collectively, “the Agreement”.

 

WHEREAS, Subtenant wishes to occupy an additional 510 square foot portion of laboratory space of the 409 Illinois Building to the space Subtenant is currently subletting from FibroGen.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

(1)          Unless otherwise defined herein, all capitalized terms and phrases used in this First Amendment shall have the meaning ascribed to them in the Sublease.

 

(2)          Section 2.1 of the Sublease is hereby deleted in its entirety and replaced with the following:

 

2.1          Conditioned upon receipt of Master Lessor’s written consent, FibroGen hereby subleases to Subtenant and Subtenant hereby takes from FibroGen certain real property as described below (the “Subleased Premises”) comprising approximately total grossed-up footprint equaling one thousand two hundred and sixty-six (1271) square feet as follows

 

(a)       In Laboratory Area #5002 (equaling to: five hundred and ten (510) square feet);

 

(b)       In the Laboratory Area #5115; Office Area #5202 and Open Area #5221 (equaling to: seven hundred and fifty-six (761) square feet); and

 

(c)        The Sublease Premises may be increased upon the mutual agreement of the Parties hereto in the form of a signed amendment to this Sublease.  However, it is expressly understood that neither Party hereto is obligated to enter into such an amendment.

 

(3)          Section 4.1 of the Sublease is hereby amended with the following:

 

4.1          Subtenant shall pay a monthly rent (“Rent”) to FibroGen for the Subleased Premises according to the following Schedule

 

	
 
    	
Months
    	
 
    	
Rent/Sq.Ft./Mo.
    	
 
    	
Total Sq. Ft.
    	
 
    	
Amount/Mo.
    	
 
    
	
 
    	
September 2010 –   January 2011
    	
 
    	
$
    	
6.80
    	
 
    	
761
    	
 
    	
$
    	
5,174.80
    	
 
    
	
 
    	
February 2011 –   September 2011
    	
 
    	
$
    	
6.80
    	
 
    	
1271
    	
 
    	
$
    	
8,642.80
    	
 
    

 

(4)          This First Amendment, together with the Sublease, contains the entire understanding of the Parties with respect to the subject matter hereof.  Except as otherwise provided herein, the Sublease has not been modified or amended and remains in full force and effect.  All express or implied agreements and understandings, either oral or written, heretofore made with respect to subject matter herein are expressly superseded in this First Amendment.

 

 

(5)          This First Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.  Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf), each of which shall be binding when sent.

 

IN WITNESS WHEREOF, the Parties have executed this First Amendment to the Sublease as of the First Amendment Effective Date.

 

	
FIBROGEN, INC.
    	
SILVER   CREEK PHARMACEUTICALS
    
	
 
    	
 
    
	
By:
    	
/s/   Pat Cotroneo
    	
 
    	
By:
    	
/s/   Ulrik Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
PAT COTRONEO
    	
 
    	
Name:
    	
ULRIK   NIELSEN
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
CFO
    	
 
    	
Title:
    	
CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
1/20/2011
    	
 
    	
Date:
    	
1/19/11
    

 

 

AMENDMENT NO. 2 TO SUBLEASE

 

THIS AMENDMENT NO. 2 (the “Second Amendment”) is effective as of May 1, 2011 (the “Second Amendment Effective Date”) by and between Silver Creek Pharmaceuticals (“Subtenant”) and FibroGen, Inc. (“FibroGen”).  This Second Amendment amends the Sublease entered into by and between Subtenant and FibroGen on August 6, 2010 (the “Sublease”), as amended pursuant to the First Amendment on February 1, 2011 (the “Prior Amendment”).  Subtenant and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”.

 

WHEREAS, Subtenant wishes to occupy an additional 83 square foot portion of open office space of the 409 Illinois Building to the space Subtenant is currently subletting from FibroGen.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

(1)          Unless otherwise defined herein, all capitalized terms and phrases used in this Second Amendment shall have the meaning ascribed to them in the Sublease as amended by the Prior Amendment.

 

(2)          Section 2.1 of the Sublease is hereby deleted in its entirety and replaced with the following:

 

2.1          Conditioned upon receipt of Master Lessor’s written consent, FibroGen hereby subleases to Subtenant and Subtenant hereby takes from FibroGen certain real property as described below (the “Subleased Premises”) comprising approximately total grossed-up footprint equaling one thousand three hundred and fifty-four (1354) square feet as follows

 

a)            In Laboratory Area #5002 (equaling to: five hundred and ten (510) square feet);

 

b)            In the Laboratory Area #5115; Office Area #5202 and Open Area #5221 (equaling to: eight hundred and forty-four (844) square feet); and

 

c)             The Sublease Premises may be increased upon the mutual agreement of the Parties hereto in the form of a signed amendment to this Sublease.  However, it is expressly understood that neither Party hereto is obligated to enter into such an amendment.

 

(3)          Section 4.1 of the Sublease is hereby amended with the following:

 

4.1          Subtenant shall pay a monthly rent (“Rent”) to FibroGen for the Subleased Premises according to the following Schedule

 

	
 
    	
Months
    	
 
    	
Rent/Sq.Ft./Mo.
    	
 
    	
Total Sq. Ft
    	
 
    	
Amount/Mo.
    	
 
    
	
 
    	
September 1, 2010 –   January 31, 2011
    	
 
    	
$
    	
6.80
    	
 
    	
761
    	
 
    	
$
    	
5,174.80
    	
 
    
	
 
    	
February 1, 2011 –   April 30, 2011
    	
 
    	
$
    	
6.80
    	
 
    	
1271
    	
 
    	
$
    	
8,642.80
    	
 
    
	
 
    	
May 1, 2011 –   August 31, 2011
    	
 
    	
$
    	
6.80
    	
 
    	
1354
    	
 
    	
$
    	
9,207.20
    	
 
    

 

 

(4)          This Second Amendment, together with the Sublease as amended by the Prior Amendment, contains the entire understanding of the Parties with respect to the subject matter hereof.  Except as otherwise provided herein and in the Prior Amendment, the Sublease has not been modified or amended and remains in full force and effect.  All express or implied agreements and understandings that conflict with the terms of this Second Amendment, either oral or written, heretofore made with respect to subject matter herein are expressly superseded by this Second Amendment.

 

(5)          This Second Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.  Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf), each of which shall be binding when sent.

 

IN WITNESS WHEREOF, the Parties have executed this Second Amendment to the Sublease as of the Second Amendment Effective Date.

 

	
FIBROGEN, INC.
    	
SILVER   CREEK PHARMACEUTICALS
    
	
 
    	
 
    
	
By:
    	
/s/   Pat Cotroneo
    	
 
    	
By:
    	
/s/   Ulrik Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Pat Cotroneo
    	
 
    	
Name:
    	
Ulrik   Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
CFO
    	
 
    	
Title:
    	
President   and CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
5/4/2011
    	
 
    	
Date:
    	
5/3/11
    

 

 

AMENDMENT NO. 3 TO SUBLEASE

 

THIS AMENDMENT NO. 3 (the “Third Amendment”) is effective as of June 15, 2011 (the “Third Amendment Effective Date”) by and between Silver Creek Pharmaceuticals (“Subtenant”) and FibroGen, Inc. (“FibroGen”).  This Third Amendment amends the Sublease entered into by and between Subtenant and FibroGen on August 6, 2010 (the “Sublease”), as amended pursuant to the First Amendment on February 1, 2011 and the Second Amendment on May 1, 2011 (the “Prior Amendments”).  Subtenant and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”.

 

WHEREAS, Subtenant wishes to occupy an additional 348.33 square foot portion of the vivarium of the 409 Illinois Building to the space Subtenant is currently subletting from FibroGen and

 

WHEREAS, Subtenant agrees to pay an additional monthly rent and charges for IACUC review relating to the vivarium space as indicated in the attached Exhibit E hereto.

 

Now, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

(1)          Unless otherwise defined herein, all capitalized terms and phrases used in this Third Amendment shall have the meaning ascribed to them in the Sublease as amended by the Prior Amendments.

 

(2)          Section 2.1 of the Sublease is hereby deleted in its entirety and replaced with the following:

 

2.1          Conditioned upon receipt of Master Lessor’s written consent, FibroGen hereby subleases to Subtenant and Subtenant hereby takes from FibroGen certain real property as described below (the “Subleased Premises”) comprising approximately total grossed-up footprint equaling one thousand seven hundred and thirty-eight point thirty-three (1738.33) square feet as follows:

 

a)            In Vivarium Area #2010, #2012, #2014, #2016, #2018 and #2024

(equaling to three hundred forty-eight point thirty-three (348.33) square  feet)

 

b)            In Laboratory Area #5002 (equaling to: five hundred and ten (510) square feet);

 

c)             In the Laboratory Area #5115; Office Area #5202 and Open Area #5221 (equaling to: eight hundred and forty-four (844) square feet); and

 

1

 

d)            The Sublease Premises may be increased upon the mutual agreement of the Parties hereto in the form of a signed amendment to this Sublease.  However, it is expressly understood that neither Party hereto is obligated to enter into such an amendment.

 

(3)          Section 4.1 of the Sublease is hereby amended with the following:

 

4.1          Subtenant shall pay a monthly rent (“Rent”)  to FibroGen for the Subleased Premises according to the following Schedule:

 

	
 
    	
Months
    	
 
    	
Rent/Sq.Ft./Mo
    	
 
    	
Total Sq. Ft.
    	
 
    	
Amount/Mo.
    	
 
    
	
 
    	
September 1, 2010 –   January 31, 2011
    	
 
    	
$6.80
    	
 
    	
761.00
    	
 
    	
$5,174.80
    	
 
    
	
 
    	
February 1, 2011 –   April 30, 2011
    	
 
    	
S6.80
    	
 
    	
1271.00
    	
 
    	
$8,642.80
    	
 
    
	
 
    	
May 1, 2011 – June 14,   2011
    	
 
    	
$6.80
    	
 
    	
1354.00
    	
 
    	
$9,207.20
    	
 
    
	
 
    	
June 15, 2011 –   August 31, 2011
    	
 
    	
$6.50/vivarium
    	
 
    	
348.33
    	
 
    	
$2,264.15
    	
 
    
	
 
    	
(lab/office/vivarium)
    	
 
    	
$6.80/office/lab
    	
 
    	
1354.00
    	
 
    	
$9,207.20
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
Total Sq. Ft.
   1738.33
    	
 
    	
Total Amt./Mo.
   $11,471.35
    	
 
    

 

(4)          A new Section 3.7 is hereby added to the Sublease as follows:

 

3.7          FibroGen may terminate Subtenant’s right to use the vivarium area specified in Section 2.1 a) above at any time by giving five business (5) days’ written notice if Subtenant misuses the vivarium area in FibroGen’s sole discretion.  A misuse shall include, but not be limited to, any failure to meet the requirements of IACUC, or any other state or federal law, regulation, or guideline.

 

(5)          Exhibit E entitled “Recap of Preclinical Facility Related Costs & Labor-Revised 4/12/11” is attached hereto and hereby added to the Sublease.

 

(6)          A new Section 5.5 is hereby added to the Sublease as follows:

 

5.5          Fees. Expenses, and costs relating to the use of the vivarium and charges for IACUC review which are listed in Exhibit E, shall be invoiced on the fifteenth (15th) day of each month immediately following the provision of the charges and shall be due and payable along with the next rent payment due after receipt of the invoice for such charges.

 

(7)          This Third Amendment, together with the Sublease as amended by the Prior Amendments, contains the entire understanding of the Parties with respect to the subject matter hereof.  Except as otherwise provided herein and in the Prior Amendments, the Sublease has not been modified or amended and remains in full force and effect.  All express or implied agreements and understandings that conflict

 

2

 

with the terms of this Third Amendment, either oral or written, heretofore made with respect to subject matter herein are expressly superseded by this Third Amendment.

 

(8)          This Third Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.  Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf), each of which shall be binding when sent.

 

 

IN WITNESS WHEREOF, the Parties have executed this Third Amendment to the Sublease as of the Third Amendment Effective Date.

 

	
FIBROGEN, INC.
    	
SILVER   CREEK PHARMACEUTICALS
    
	
 
    	
 
    
	
By:
    	
/s/   Pat Cotroneo
    	
 
    	
By:
    	
/s/   Ulrik Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Pat Cotroneo
    	
 
    	
Name:
    	
Ulrik   Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
CFO
    	
 
    	
Title:
    	
CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
5/26/11
    	
 
    	
Date:
    	
5/26/11
    

 

3

 

Exhibit E
  Recap of Preclinical Facility Related Costs & Labor — Revised 4/12/11

 

I.                 VIVARIUM Administration:

 

	
FTE   SUPPORT per Microcompany
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
*ADMINISTRATION
    	
 
    	
 
    	
 
    
	
(1) ASP   Protocol, (1) Yearly Renewal, and up to (1) Amendment
   (committee submission / PI notifications / records management)
    	
 
    	
 
    	
 
    
	
(1) Animals   Order
   (review, enter requisition, obtain PO, place order w/vendor, email order   confirmations)
    	
 
    	
 
    	
 
    
	
(1) Animal   Receipt
   (manage animal orders / health / animal census records, prepare animal ID cage   cards)
    	
 
    	
 
    	
 
    
	
Order   Food, Bedding, Disposable Supplies
   (place orders w/vendors, receive / store / distribute)
    	
 
    	
 
    	
 
    
	
Training   Program
   (coordinate training / procedure evaluations w/IACUC designated   trainers/qualifiers, training record management)
    	
 
    	
 
    	
 
    
	
Compliance   Oversight
   (animal welfare / IACUC protocol / institutional policies / preclinical   facility policies / standard procedures / regulatory agencies monitoring and   enforcement)
    	
 
    	
 
    	
 
    
	
Occupational   Health & Safety for Vivarium Users
   (new user orientation & safely training, material documentation,   updates, records management)
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    

	
*Above is based on one (1) Protocol   per year (including up to one   (1) Amendment) and 1 animal order per   month
    
	
5 hours/company/month @ $100/hr à $500/company/month
    

 

4

 

II.             HUSBANDRY Services:

 

 

	
FTE   SUPPORT for 200 MICE
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
HUSBANDRY
    	
 
    	
 
    	
 
    
	
Animal   Receipt (pick-up from warehouse, disinfect shipping crates, uncrate animals   and distribute into prepared housing units, remove identifying labels from   crates, stack crates for disposal, sweep & disinfect receiving area,   submit receiving paperwork to office)
    	
 
    	
 
    	
 
    
	
Cage   Unit Set-Up (cages, fill cages w/bedding, cage lids, cage filter tops, cage   card holders, cage identification cards, enrichment objects/nesting   materials/snacks, rodent food, fill water bottles)
    	
 
    	
 
    	
 
    
	
Cage   Exchanges (load clean cage units onto cart and transport to animal holding   room and relocate animals from soiled cage units into clean prepared cage   units)
    	
 
    	
 
    	
 
    
	
Soiled   Cage Unit Break-Down (load soiled cage units onto cart and transport from   animal holding room to dirty wash room, discard food, empty water bottles,   remove cage unit objects and sort into washer containers, discard soiled   bedding, empty soiled trash bins, sweep & disinfect dirty wash room)
    	
 
    	
 
    	
 
    
	
Cage   Washing (load cages into cage washer, cage washer operation, unload cages   from cage washer)
    	
 
    	
 
    	
 
    
	
Animal   Holding Room Racks and Floor Sanitation
    	
 
    	
 
    	
 
    
	
Animal   Holding Room Complete Sanitation
    	
 
    	
 
    	
 
    
	
Animal   Health Observations / Holding Room Environmental Control Documentation
   (7 days/week, 365 days/yean assess animal health of general   population & document, assess health of post-op/post-procedural   animals & document, check food & water levels (supplement   if necessary), document room temperature & humidity, check   temperature setting & water levels in water circulating heating pads   (supplement if necessary)
    	
 
    	
 
    	
 
    
	
200 MICE   (50 Cages)
    	
 
    
	
 
    	
 
    
	
30 hours/week @ $20/hr =   $600/week = $2400/month à $800/company/month
    

 

5

 

III.     FOOD & BEDDING Estimates:

 

Monthly FOOD estimate for 200 mice:  ~3 bags/month @$27.50/bag à  $82.50/month

 

Monthly BEDDING estimate for 200 mice:  ~6 bags/month @$11/bag à  $66/month

 

Food & Bedding cost estimate for 200 mice  =  $148/month  à

$49.33/company/month

 

Monthly Costs without IACUC and /or Veterinary Services, per company:

 

	
 
    	
 
    	
$ 500.00 Administration
    
	
 
    	
 
    	
$800.00 Husbandry Services
    
	
 
    	
 
    	
$ 49.33 Food and Bedding
    	
 
    
	
 
    	
Total:
    	
$1,349.33   per month per sub-tenant
    

 

 

(Does not include IACUC and /or Veterinary Services)

 

 

IV.                                FibroGen’s IACUC Committee  à  billed per activity below:

 

·                  IACUC ASP Committee Review Process @ $1000/ASP protocol

(6 IACUC members @ $100/member x ~1.75 hours/member/ASP review)

·                  IACUC ASP Annual Renewal Committee Review Process @ $500/ASP

(6 IACUC members @ $100/member x ~.75 hours/member/ASP renewal)

·                  IACUC ASP AMENDMENT full Committee Review Process @ $200/Amendment

(6 IACUC members @ $100/member x ~.33 hours/member/ASP Amendment)

 

V.                                    Veterinary Services  à  billed per services rendered below:

 

·                  Teleconference / Conference Calls @ $200/hr

·                  On-Site Training Services @ $200/hr

·                  Hands On Training

·                  Standard Procedure Qualification Evaluation

·                  Animal Health Evaluation / Treatments @ $200/hr

 

6

 

AMENDMENT NO. 4 TO SUBLEASE

 

THIS AMENDMENT NO. 4 (the “Fourth Amendment”) is effective as of August 1, 2011 (the “Fourth Amendment Effective Date”) by and between FibroGen, Inc. (“FibroGen”) and Silver Creek Pharmaceuticals (“Subtenant”).  This Fourth Amendment amends the Sublease entered into by and between Subtenant and FibroGen on August 6, 2010 (the “Sublease”), as amended pursuant to the First Amendment on February 1, 2011, the Second Amendment on May 1, 2011 and the Third Amendment on June 15, 2011 (collectively, the “Prior Amendments”).  Subtenant and FibroGen shall be referred to individually herein as a “Party”, and collectively as, the “Parties”.

 

WHEREAS, Subtenant wishes to continue subleasing certain designated office and laboratory space from FibroGen in the 409 Illinois Building;

 

WHEREAS, Subtenant wishes to vacate 510 square feet in laboratory #502 and 307 square feet in laboratory #5115;

 

WHEREAS, Subtenant wishes to add 830 square feet for one half of laboratory #4034/4036; and

 

WHEREAS, Monthly rent for laboratory and office space will be reduced from the rate of $6.80 per square foot per month to the rate of $6.60 per square foot per month.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

(1)          Unless otherwise defined herein, all capitalized terms and phrases used in this Fourth Amendment shall have the meaning ascribed to them in the Sublease as amended by Prior Amendments.

 

(2)          Section 2.1 of the Sublease is hereby deleted in its entirety and replaced with the following:

 

“2.1        Conditioned upon receipt of Master Lessor’s written consent, FibroGen hereby subleases to Subtenant and Subtenant hereby takes from FibroGen certain real property as described below (the “Subleased Premises”) comprising of approximately the total grossed-up footprint equaling one thousand seven hundred and fifteen point thirty-three (1,715.33) square feet as follows:

 

a)              In Vivarium Area #2010, #2012, #2014, #2016, #2018 and #2024.  Total grossed up area equals three hundred forty-eight point thirty-three (348.33) square feet.

 

b)             Subtenant will add 1/2 of Laboratory #4034/#4036.  Total grossed-up area equals eight hundred and thirty (830) square feet.

 

c)              Subtenant will vacate Laboratory Area #5002.  Total grossed-up area equals five hundred and ten (510) square feet.

 

d)             Subtenant will vacate Laboratory Area #5115.  Total grossed up area equals three hundred and seven (307) square feet.

 

e)              Office Area #5202 and Open Area #5221.  Total grossed-up area equals five hundred and thirty seven (537) square feet.

 

 

f)                The Sublease Premises may be increased upon the mutual agreement of the Parties hereto in the form of a signed amendment to this Sublease.  However, it is expressly understood that neither Party hereto is obligated to enter into such an amendment.”

 

(3)          Section 3.2 of the Sublease is hereby deleted in its entirety and replaced with the following:

 

“3.2        This Sublease will expire on:

 

a)              September 1, 2012 (“Expiration Date “)

 

b)             Subtenant shall have the option to extend term of lease for one additional six (6) month term by giving thirty (30) days written notice no later than thirty days from the Expiration Date stated in Section 3.2a “

 

(4)          Section 4.1 of the Sublease is hereby amended with the following:

 

“4.1        Subtenant shall pay a monthly rent (“Rent”) to FibroGenfor the Subleased Premises according to the following schedule:

 

	
Months
    	
 
    	
Rent/Sq.Ft./Mo.
    	
 
    	
Total Sq. Ft.
    	
 
    	
Amount/Mo.
    
	
September 1, 2010-January 31, 2011 (Lab/Office)
    	
 
    	
$6.80
    	
 
    	
761.00
    	
 
    	
$5,174.80
    
	
February 1 ,2011 -April 30, 2011 (Lab/Office)
    	
 
    	
$6.80
    	
 
    	
1271.00
    	
 
    	
$8,642.80
    
	
May 1, 2011-June 14, 2011 (Lab/Office)
    	
 
    	
$6.80
    	
 
    	
1354.00
    	
 
    	
$9,207.20
    
	
June 15, 2011-July 31 ,2011 (Lab/Office/Vivarium)
    	
 
    	
$6.50/Vivarium $6.80/Office/Lab
    	
 
    	
348.33 1354.00 Total Sq. Ft. 1738.33
    	
 
    	
$2,264.15 $9,207.20 Total Amt./Mo. $11,471.35
    
	
August 1, 2011-August 7, 2011 (Lab/Office/Vivarium)
    	
 
    	
$6.50/Vivarium $6.80/Office/Lab
    	
 
    	
348.33 1354.00 Total Sq. Ft. 1715.33
    	
 
    	
$511.28 $2,079.00 Total Amt. $2,590.28
    
	
August 8, 2011-August 31, 2011* (Lab/Office/Vivarium)
    	
 
    	
$6.50/Vivarium $6.60/Office/Lab
    	
 
    	
348.33 1367.00 Total Sq. Ft. 1715.33
    	
 
    	
$1,752.87 $6,984.96 Total Amt. $8,737.83
    
	
September 1, 2011-September 1, 2012 (Lab/Office/Vivarium)
    	
 
    	
$6.50/Vivarium $6.60/Office/Lab
    	
 
    	
348.33 1367.00 Total Sq. Ft. 1715.33
    	
 
    	
$2,264.15 $9,022.20 Total Amt./Mo. $11,286.35
    

 

*Note: Pro-Rated Rent Payment”

 

(5)          This Fourth Amendment, together with the Sublease as amended by the Prior Amendments, contains the entire understanding of the Parties with respect to the subject matter hereof. Except as otherwise provided herein and in the Prior Amendments, the Sublease has not been modified or amended and remains in full force and effect.  All express or implied agreements

 

 

and understandings that conflict with the terms of this Fourth Amendment, either oral or written, heretofore made with respect to subject matter herein are expressly superseded by this Fourth Amendment.

 

(6)          This Fourth Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument.  Counterparts may be signed and delivered by facsimile and/or via portable document format (pdf) (or similar format), each of which shall be binding when sent.

 

IN WITNESS WHEREOF, the Parties have executed this Fourth Amendment to the Sublease as of the Fourth Amendment Effective Date.

 

	
FIBROGEN, INC.
    	
 
    	
SILVER   CREEK PHARMACEUTICALS
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
By:
    	
/s/   Rod Fuhriman
    	
 
    	
By:
    	
/s/   Ulrik Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
Rod   Fuhriman
    	
 
    	
Name:
    	
Ulrik   Nielsen
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Controller
    	
 
    	
Title:
    	
CEO
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
7/29/11
    	
 
    	
Date:
    	
7/29/11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]